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ABSTRACT
Whole-genome sequencing data allow detection of
copy number variation (CNV) at high resolution. How-
ever, estimation based on read coverage along the
genome suffers from bias due to GC content and
other factors. Here, we develop an algorithm called
BIC-seq2 that combines normalization of the data
at the nucleotide level and Bayesian information
criterion-based segmentation to detect both somatic
and germline CNVs accurately. Analysis of simula-
tion data showed that this method outperforms exist-
ing methods. We apply this algorithm to low cover-
age whole-genome sequencing data from peripheral
blood of nearly a thousand patients across eleven
cancer types in The Cancer Genome Atlas (TCGA) to
identify cancer-predisposing CNV regions. We con-
firm known regions and discover new ones including
those covering KMT2C, GOLPH3, ERBB2 and PLAG1.
Analysis of colorectal cancer genomes in particular
reveals novel recurrent CNVs including deletions at
two chromatin-remodeling genes RERE and NPM2.
This method will be useful to many researchers in-
terested in profiling CNVs from whole-genome se-
quencing data.
INTRODUCTION
DNA copy number variation (CNV) is a major class of
genome variations in the human genome. Germline CNVs
are inherited genetic events that could confer susceptibil-
ity to various types of cancer (1–3) as well as other dis-
eases (4,5). Somatic CNVs are de novo genetic events that
could result in diseases, e.g. deletion of tumor suppres-
sors or amplification of oncogenes can drive tumorigen-
esis (6). With whole-genome sequencing (WGS) becom-
ing more common, there are opportunities to characterize
CNVs with a greater spatial resolution than ever before, but
accurate and efficient algorithms must be applied to detect
small-scale CNVs while avoiding false positives.
Among the available detection algorithms forWGS data,
paired-end mapping (PEM) methods (7–9) identify CNVs
by analyzing the configuration of read pairs. These methods
are advantageous in their high resolution and their sensitiv-
ity for detecting small events. However, when the configura-
tion of CNVs is complex, PEM-based method can have low
sensitivity. Read-depth methods (10–16) instead can read-
ily detect these complex CNVs as long as they are relatively
large.
Read-depth methods detect CNVs by identifying regions
with abnormal sequencing read coverage along the genome,
as the presence of CNVs leads to increased or decreased
sequencing coverage in those regions. However, sequenc-
ing coverage can be easily affected by various biases in-
cluding the influence of GC-content in the sequenced frag-
ments, the regional variation in the fraction of short reads
that can be uniquely aligned, and different nucleotide com-
position of short reads (17). For somatic CNVs, one strat-
egy for dealing with these biases is to compare to a con-
trol (13,14). This approach is model-independent and can
capture even unknown sources of biases; but sequencing a
control genome doubles the experimental cost, assumes that
the biases in the case and control are the same and cannot
be used for germline CNVs. Another bias-correction strat-
egy (10–12,15,16) is to explicitly incorporate a mathemati-
cal model for bias correction to normalize data. However,
most current algorithms (10–12) simply bin the data into
equal-sized bins and perform normalization based on the
binned data with GC and/or mappability (proportion of
uniquely mappable positions in a bin) as explanatory vari-
ables. The choice of the bin size is often a subtle but criti-
cal parameter, as it has to balance detection resolution and
control of the noise level. The best choice of the bin size de-
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pends on the read depth: for high depth data, a small bin
size can adequately control the noise level, but this is not
the case for low depth data. Although equal-sized bins are
simple, they can contain a substantially different number of
mappable positions, resulting in high variance of some data
points that potentially mask real copy number change sig-
nals.
In this paper, we present BIC-seq2 for detecting somatic
and germline CNVs based on WGS data. Whereas the first
version in 2011 used a control genome for normalization
(13) and was thus limited to identification of somatic vari-
ants, the new version is also applicable to germline vari-
ants and is more robust overall. This algorithm first nor-
malizes the sequencing data by taking into account the GC-
content, the nucleotide composition of the short reads and
the mappability. It then performs segmentation and detects
CNVs based on the normalized data using a Bayesian in-
formation criterion.Unlike other algorithms, BIC-seq2 per-
forms normalization at a nucleotide level rather than at a
large bin level, resulting in its high sensitivity of detection
for small CNVs. If there is a control genome or a sample
was sequenced on multiple runs, we perform normalization
individually for each data set and perform joint segmenta-
tion for CNV detection. To demonstrate the superior per-
formance of BIC-seq2, we compared it with a number of
other read-depth methods on a set of simulated sequenc-
ing data sets and a data set from the 1000 Genome Project
(NA12878).We then applied it to data sets fromTheCancer
Genome Atlas (TCGA) to identify novel regions of cancer
susceptibility.
MATERIALS AND METHODS
Overview of BIC-seq2
BIC-seq2 has two main steps, the normalization step and
the segmentation step. In the normalization step, BIC-seq2
models the number of reads mapped to a position in the
mappability map (i.e. positions to which a read can be
aligned under given criteria) to be dependent on local ge-
nomic features such as GC-content. This model is a semi-
parametric regression model that can calculate the expected
number ofmapped reads for every position in themappabil-
ity map. This regression model accounts for known sources
of bias; thus, the ratio between the observed number and
the expected number of mapped reads in a region would re-
flect just the copy number of the region. A significant differ-
ence between the ratios of two regions implies that the copy
numbers of the two regions are different. In the segmenta-
tion step, BIC-seq2 employs the BIC-seq segmentation al-
gorithm (13). This algorithm is based on a non-parametric
model and performs segmentation by iteratively merging
similar neighboring bins. In each iteration, the neighboring
bin pair whose merging will lead to the largest reduction
of the Bayesian information criterion (BIC) are merged. At
the last step, BIC-seq2 performs post-processing to calcu-
late copy ratios and assign P-values.
In addition to uniquely aligned reads, BIC-seq2 can also
incorporate reads that can be aligned to multiple positions
(‘multiply-aligned’ reads) if desired. The mapping position
of a multiply-aligned read is randomly chosen as one of its
mapped positions. If only uniquely aligned reads are used,
the mappability map consists of all uniquely mappable po-
sitions in the genome; if multiply-aligned reads are consid-
ered, it consists of the non-N regions. The uniquely map-
pable positions were downloaded from the UCSC Genome
Browser (CRG mappability track). For a given read length
k, a position is considered to bemappable if the k-mer start-
ing at that position has only one mapped position (itself) in
the genome while allowing for twomismatches. Supplemen-
tary Figure S1A shows the percentages of uniquely map-
pable positions in the human reference genome hg19 for k
= 36, 50, 75 and 100. If only uniquely aligned reads are used,
BIC-seq2 has a lower power for CNVs in repetitive DNA;
if multiply-aligned reads are used, it has a higher false dis-
covery rate.
Normalization of sequencing data
Statistical model. For every position in the mappabil-
ity map, the number of reads mapped to this position is
counted. In addition to the local copy number, this read
count also depends on local genomic features. We employ
a generalized additive model (GAM) to describe this de-
pendence. At each genomic position s in the mappability
map, we model ys, the number of mapped reads starting at
the position s, as a quasi-Poisson model with its mean de-
pending on local genomic features. The random variable ys
is assumed to have a mean λs > 0, and the mean λs depends
on the localGC-content and nucleotide compositions of the
sequences around the reads. We assume
log (λs) = f (GCs) + g (NCs) , (1)
where GCs is the GC-proportion in a local genomic win-
dow of s, NCs is the nucleotide compositions around s,
and f, g are unknown functions. The GC window is cho-
sen as themean fragment size since GC-bias is mainly intro-
duced in the polymerase chain reaction (PCR) amplification
step during library construction (18). This fragment size can
be easily estimated with paired-end sequencing data. Nu-
cleotide composition was introduced in the model because
it was shown to influence read-depth ofWGS, although to a
lesser degree than for RNA-seq (17). We only consider nu-
cleotide compositions near the ends of short reads (default
5 bp of the ends) because their influence is restricted to the
ends of the reads (17) (also see Supplementary Figure S1B).
The choice of the function form of f can have important ef-
fect on how well the regression model can explain the data.
One choice is to assume a parametric form such as polyno-
mials of fixed degree (11). The polynomial-based regression
is advantageous in its simplicity and its ease of interpre-
tation. However, we observe that the GC-dependence can
take various forms (Supplementary Figure S2). If the func-
tion form is mis-specified, the model can be biased. There-
fore, we choose to use splines, a non-parametric method,
to estimate f. Since nucleotide compositions are categorical
variables, the function g is the summation of indicator func-
tions. Details of the model are given in the Supplementary
Text.
Model training and refinement. To estimate the parameters
in the above GAM, we adopt the method as proposed by
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Woods (2008) (19). With the human reference genome hav-
ing over 2 billion uniquely mappable positions, it is very dif-
ficult to estimate the parameters with all the data. Therefore,
we choose to randomly select a small portion of the entire
data set (e.g. 1%) and train themodel only based on the ran-
domly sampled data. After fitting the GAM, an expected
read count can be calculated for each mappable position.
However, we observe that the ratio between the observed
and the expected number of reads still have some correlation
with the GC-content (Supplementary Figure S3), possibly
due to the insufficient sampling of regionswith extremeGC-
contents.
To remove this correlation, we introduce an additional
step to refine the predicted value by the GAM. This refine-
ment step captures the remaining GC-dependence on a rel-
atively large bin level. Here the bins are variable-sized bins
containing the same number of mappable positions. The log
ratios of the observed and the expected number of reads in
the bins are regressed against the proportions of GC in the
bins. The regression is again based on a GAM. If the model
(1) captures all GC-dependence, the fitted curve of the log
ratio model should be a horizontal straight line at y= 0, i.e.
for each GC-proportion, its fitted value of log ratio should
be zero or close to zero. The deviance of the fitted value
from zero is the uncaptured dependence onGC-content.We
then adjust the expected number of reads given by model
(1) using fitted values from this log-ratio-vs-GC regression
model. Briefly, let λˆs be the predicted read count at a map-
pable position s, and GCs be its local GC-proportion. Sup-
pose that hˆ(GCs) is the fitted value for GC = GCs from the
log-ratio-vs-GC regression model. We refine the expected
read count at s to be λˆshˆ(GCs). Details of the refinement
step are given in the Supplementary Text.
Segmentation and post-processing. After normalization,
BIC-seq2 utilizes the BIC-seq segmentation algorithm to
perform segmentation. BIC-seq detects somatic CNVs by
comparing a tumor genome with its matched genome.
Given an initial set of bins, BIC-seq performs segmenta-
tion based on each bin’s read counts of the tumor and nor-
mal genomes, and the bins are iteratively merged to give the
final segmentation. Specifically, suppose that at one merg-
ing step, the remaining bins are bi (i = 1, 2, · · · ,m). Let Ti
and Ni be the numbers of reads for the case and the control
genome in the bin si. The BIC is defined as
BIC =
−2∑mi =1
[
Ti log
(
Ti
Ti+Ni
)
+ Ni log
(
Ni
Ti+Ni
)]
+ λmlog(N), (2)
where N =
m∑
i=1
(Ti + Ni) and λ is a tuning parameter. BIC-
seq merges the bin pair (bi, bi+1) such that the merging can
give the largest reduction of the BIC. BIC-seq stopsmerging
if merging of any bin pair cannot further reduce the BIC.
In BIC-seq2, let Oi and Ei be the observed and expected
numbers of reads in the bin bi. BIC-seq2 sets Ti = Oi and
Ci = Ei in (2) to perform the segmentation.
Because equal-sized bins can contain substantially differ-
ent numbers of mappable positions, the number of reads in
those bins tend to have higher variance, potentially masking
real copy number changes (Figure 1A). Even if we remove
the bins with low mappability, the number of reads in the
remaining bins still tend to have high variance, resulting in
ambiguous copy number states (Supplementary Figure S4).
When we choose the initial bins as variable-sized bins with
each bin containing the same number of mappable posi-
tions, the copy number states become much clearer (Figure
1B). Note that variable-sized bins contain equal numbers of
mappable positions, but not equal number ofmapped reads,
as is done in some methods. After segmentation, the log2
copy ratio of each segment is defined as the log2 ratio of
the observed read count and the expected read count of the
segment. Finally, we assign P-values to the log2 copy ratios
of all segments based on permutation. Specifically, given a
segment and its log2 copy ratio x, suppose that the segment
contains M initial bins. At each permutation, we randomly
selectMnon-contiguous bins from the initial set of bins and
we can calculate a log2 copy ratio based on these M bins.
By repeating this process B times (e.g. 1000), we obtain B
log2 copy ratios. Supposing that μ is the mean and σ is the
standard deviation of these B log2 copy ratios, the P-value
of the segment is calculated as the probability P(|X| > x),
with the random variable X following the normal distribu-
tion N(μ, σ 2).
CNV detection for samples with data from multiple lanes and
somatic CNV detection
To increase sequencing coverage, samples are often se-
quenced in multiple lanes or at multiple times. A typical
strategy is simply to call CNVs after pooling all the data,
implicitly assuming that the biases in all data sets are the
same.We observe that this assumptionmay not be true (Fig-
ure 1C and D), suggesting that the simple pooling strategy
could lead to a high false positive rate. Therefore, BIC-seq2
instead performs normalization for each data set separately
and performs segmentation jointly using the multi-sample
BIC-seq segmentation (13). Suppose that there are K data
sets for a sample. Let Oki and Eki be the observed and the
expected numbers of reads for the kth data set in the bin bi.
BIC-seq2 then iteratively merges bin pairs by improving the
following
BIC =
−2∑Kk=1
∑m
i =1
[
Oki log
(
Oki
Oki+Eki
)
+ Eki log
(
Eki
Oki+Eki
)
+
]
+ λKmlog(N), (3)
where N =
K∑
k=1
m∑
i=1
(Oki + Eki). After segmentation, each seg-
ment will have K estimates of log2 copy ratios correspond-
ing to K data sets. BIC-seq2 defines the log2 copy ratio of a
segment as the mean of its K log2 copy ratios. For somatic
CNV detection, BIC-seq2 first normalizes tumor and nor-
mal genomes separately and performs multi-sample BIC-
seq joint segmentation (K = 2 in Equation (3)). The log2
copy ratios for the tumor (normal) genome are defined as
the log2 ratios between the observed and expected number
of tumor (normal) reads in the segments. BIC-seq2 also fil-
ters germline CNV events by removing regions with log2
copy ratios for the normal genome <−0.2 or >0.2. In all
of the following analyses, BWA (20) was used for alignment
of the reads with read length <100 bp. If the read length is
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Figure 1. GC bias revealed by fix-sized bins and variable-sized bins. (A) The low-coverage WGS data from a TCGA sample (TCGA-AG-3574) are binned
to equal-sized bins (10 Kb). There is no clear pattern of GC-dependence. (B) The data are binned to variable-sized bins with equal number of mappable
positions (10 K). This shows clear positive GC-dependence and bands corresponding to different copy number states. (C andD) Two lanes of the individual
NA19240 in the same library show different GC dependence.
≥100bp, BWA-MEM was used, but the hard-clipped reads
were removed before analysis.
RESULTS
Characterization of GC bias
We applied the normalization procedure to a hundred
genomes from the 1000 Genome Project to evaluate its per-
formance (Supplementary Table S1; see the Supplemen-
tary Text for more descriptions). The 50-bp reads in these
genomes were mapped to the human reference genome
hg18. To assess GC bias, we computed the correlation be-
tween the read count and the GC-content (Figure 2A). We
observe that the dependence of read count on GC-content
varies significantly across the samples with the correlation
spanning a wide range and negative in most cases. After
normalization, we can see that GC-dependence has been ef-
fectively removed and the observed/expected ratio has al-
most no correlation with GC for all samples considered.
Supplementary Figure S2 shows the effect of the normal-
ization procedure for three other HapMap genomes from
the 1000Genomes. The read counts in two samples (Supple-
mentary Figure S2A and B) show particularly strong non-
linear GC-dependency, but the observed/expected ratio af-
ter normalization shows no evidence of GC-dependency
(Supplementary Figure S2D and E). These results demon-
strate that the normalization procedure can accurately cap-
ture and remove the non-linear GC-dependency. Even if we
include the multiply-aligned reads, this normalization pro-
cedure can also effectively remove the GC biases (Supple-
mentary Figure S5A). Figure 2B shows the effect of the nor-
malization on the tumor genome that was shown in Figure
1B (the read length is 50 bp). In this example, the tumor
genome has a strong positive correlation with GC-content
and the dependence of the tumor read count onGC-content
is nonlinear. After normalization, we can see the correlation
with GC-content is successfully removed. We further com-
pared the distribution of copy ratio estimates for variable-
sized bins and equal-sized bins (Figure 2C top and mid-
dle panel). The variable-sized bins contain 10 Kb uniquely
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Figure 2. Effectiveness of the normalization procedure in BIC-seq2. (A) The normalization procedure was applied to a hundred genomes from the 1000
Genome project. The boxplots of Spearman’s correlation with GC-content at three different levels before (the observed read count) and after (the ratio
between the observed and the expected read counts) normalization are shown. This demonstrates that nearly all GC-dependency is removed. The bins with
equal number of uniquely mappable positions were used. (B) For the TCGA sample in Figure 1 A and B, the GC-dependency is entirely removed after
normalization. (C) The BIC-seq2 normalization in variable-sized bins containing 10 Kb mappable positions shows well-defined peaks corresponding to
different copy number states (top panel), while the same normalization in 10 Kb equal-sized bins is diffuse with little separation of different copy number
states (middle panel). A simple normalization by the matched normal (tumor/normal ratios) in variable-sized bins shows no clear separation of different
copy number states (bottom panel).
mappable positions and the equal-sized bins are 10Kb bins.
The distribution for the variable-sized bins shows a very
clear separation of different copy number states, but the one
for the equal-sized bins has no clear peaks. Since the bi-
ases in tumor and normal genomes are different (Figure 1B
and Supplementary Figure S5B), the tumor/normal copy
ratios in the variable-sized bins also have no clear separa-
tion among regions with different copy numbers (Figure 2C
bottom panel). Supplementary Figure S5C and D show the
effect of the normalization on a tumor genome with 100 bp
data, which again shows that the normalization is effective
in removing GC-biases.
Simulation study
We first used simulation to study the performance of BIC-
seq2 forCNVdetection. In the simulation, we generated 100
pseudo-chromosomes harboring 42 CNVs (6 copy number
levels × 7 CNV size levels) based on chromosome 22 of the
human reference genome (hg18). The CNVs were randomly
placed on the pseudo-chromosomeswith a requirement that
each CNV segment cannot have more than 20% Ns. The
program metaSim (21) was used to simulate 50 bp reads
from the pseudo-chromosomes, and GC-biases were fur-
ther introduced (the Supplementary Text and Supplemen-
tary Figure S6). The reads were then mapped back to chro-
mosome 22 with BWA allowing two mismatches. We gener-
ated 3 data sets for each pseudo-chromosome at 3 different
sequencing coverage levels.
We considered two scenarios for BIC-seq2: using only
uniquely mapped reads and using all reads including the
multiply-aligned reads. We normalized data and set the ini-
tial bin size as 10 bp for segmentation. The penalty param-
eter λ was chosen as 1.2. The candidate CNV regions were
chosen as regions withP-values less than 0.01 and log2 copy
ratio >0.2 or <−0.2. For comparison, we also applied CN-
Vnator (10), FREEC (11) and ReadDepth (12) to the sim-
ulated data. For CNVnator, we chose the initial bin size to
be 500 bp as it performed the best at this bin size. Default
parameters were used for FREEC andReadDepth. Of note,
since CNVnator and FREEC often predict gaps in the ref-
erence genome as deletions, we removed their CNV predic-
tions overlapping these gaps in the comparison. If we do
not remove these predictions, CNVnator has significantly
more false discoveries (Supplementary Figure S7). We also
applied the same filtering to BIC-seq2, FREEC and Read-
Depth predictions to make the comparison fair (though it
is not necessary for BIC-seq2).
Figure 3 shows the sensitivity of the five algorithms for
detecting the following groups of CNVs: 2-copy deletions,
1-copy deletions, 1-copy gains, 2-copy gains and 3-copy
gains. The sensitivity plots for 4-copy gains are shown in
Supplementary Figure S7A–C. Here, a predicted CNV is
defined as a true positive if it overlaps at least 50% with
a simulated CNV. Overall, we can see that the two ver-
sions of BIC-seq2 achieve the highest sensitivity at all se-
quencing depths, though BIC-seq2-Unique is a little less
sensitive for detecting large CNVs (10 kb, 50 kb and 100
kb) compared with BIC-seq2-Nonunique, CNVnator and
ReadDepth. This is because CNVs in non-uniquely map-
pable regions cannot be detected by only uniquely map-
pable reads. For smaller CNVs, both versions of BIC-seq2
generally are significantly more sensitive than other algo-
rithms. For example, at 30x coverage, the powers of both
BIC-seq2-Unique and BIC-seq2-Nonunique at detecting 1
kb homozygous deletions are over 90%, but the correspond-
ing powers for FREEC, CNVnator and ReadDepth are
only around 40%, 20% and 0%.The false discovery rates for
BIC-seq2-Unique, CNVnator and FREEC are all very low
(close to 0 on average) (Supplementary Figure S7D,E and
F). The false discovery rates for BIC-seq2-Nonunique are
a little higher than the three aforementioned algorithms,
because some parts of the true copy gain regions are not
uniquely mappable and reads from these regions may be
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Figure 3. Performance of BIC-seq2, CNVnator, FREEC and ReadDepth for simulated data. BIC-seq2-Unqiue: only uniquely mapped reads; BIC-seq2-
Nonunique: all mapped reads are used, with a randomly sampled position when the reads are multiply-aligned. (A1–A5) At 3X coverage, the sensitivities
for (A1) 2-copy deletions, (A2) 1-copy deletions, (A3) 1-copy gains, (A4) 2-copy gains and (A5) 3-copy gains. (B1–B5) and (C1–C5) are similar plots but
at 10X and 30X coverages.
randomly mapped to other non-CNV regions. Hence, these
non-CNV regions will have increased sequencing depth and
will be detected by BIC-seq2 as copy gains when the se-
quencing depth is high enough. For this reason, we will only
use BIC-seq2-Unique in the following real data analyses
(thus BIC-seq2 refers to BIC-seq2-Unique in the rest of the
paper). The false positives for ReadDepth are significantly
more than other algorithms. Taken together, we conclude
that BIC-seq2 can predict more small CNVs with similar or
fewer false discoveries compared with other algorithms.
CNV detection comparison on a normal genome
We applied BIC-seq2, CNVnator, FREEC and ReadDepth
to the NA12878 sample from the 1000 Genome Project.
Since this data set consists of data sequenced from four
libraries, we normalized the data separately for each sub-
set (although the biases were very similar in this case)
and performed joint segmentation for CNV detection with
BIC-seq2. For other algorithms, we applied the same pa-
rameter setup as in the simulation study. To compare the
performance of these algorithms, we overlapped the copy
losses predicted by the algorithms with the deletions re-
ported in Mills et al. (22) where the authors catalogued
experimentally-validated deletions of this individual after
prediction by a set of algorithms. Specifically, we took all
deletion predictions of NA12878 that were marked as vali-
dated and the deletions in the gold standard sets of the pa-
per and merged overlapping deletions as deletion regions.
The deletion predictions of the four algorithms are consid-
ered true positives if they overlap by 50% with any of these
deletion regions. BIC-seq2 has the highest true positive rate
(TPR) (83%), and then followed by FREEC (81%), Read-
Depth (63%) and CNVnator (60%).
Next, we applied each algorithm separately to the four li-
braries of NA12878 to investigate replicability of CNV pre-
dictions. A CNV called from one library is marked as repli-
cated by another library if it is covered by CNVs of the same
type called from the second library. Figure 4A shows the
percentages of replicable CNVs from all pair-wise compar-
isons. We clearly see that BIC-seq2 has the highest percent-
age (∼95%) of replicated CNVs. Similar to the above result,
FREEC performs better than CNVnator and ReadDepth,
but its percentage of replicated CNVs is consistently less
that of BIC-seq2. Figure 4B shows the CNVs on the first
half of chromosome 1 called based on each library given
by BICseq2, FREEC, CNVnator andReadDepth (See Sup-
plementary Figure S8 for examples of other chromosomes).
This plot clearly shows that BIC-seq2 gives consistent calls
6280 Nucleic Acids Research, 2016, Vol. 44, No. 13
Figure 4. Replicability and profile comparison. (A) The boxplots of the percentages of replicable CNVs detected from the four libraries of NA12878. Each
pair of libraries was compared. (B) The CNVs in the first half of chromosome 1 detected by BIC-seq2, FREEC, CNVnator and ReadDepth in the 4
libraries.
across the libraries, whereas other algorithms give many
calls that are not stable across the libraries.
CNV detection in colorectal cancer genomes
Comparison with microarray data. To further evaluate the
performance of BIC-seq2, we applied it to a hundred pairs
of low coverage colorectal tumor and matched control
(blood) genomes available fromTCGA (Supplementary Ta-
ble S2). The parameter setup was set as before. The CNV
predictions are taken as regions with log2 tumor/expected
ratio >0.2 or <−0.2. These cutoffs are often used by other
TCGA studies. We also filtered regions harboring likely
germline variations, i.e. regions with log2 control/expected
ratios >0.2 and <−0.2. Since array-based copy number
measurements on the same samples have been widely used
(23), we sought to compare the copy number calls from
the array and sequencing platforms. We found that the log2
tumor/expected ratio highly correlated with corresponding
log2 copy number ratios of the array data (the ‘seg.mean’
values; Spearman’s correlation: 0.95; Figure 5A). Under the
criterion that a copy gain (loss) is defined as a true posi-
tive if its corresponding log2 copy ratio of the array data
is greater (less) than 0.2 (−0.2), the true positive rate of
BIC-seq2 is 90.8%. We further performed linear median re-
gression with the log2 copy number ratios of the array data
as the response variable and the log2 tumor/expected ra-
tio as the predictor (Figure 5A). The estimated intercept is
−0.041 (sd = 0.002) and the estimated slope is 1.038 (sd =
0.002). Since we would expect the intercept of this regres-
sion model to be 0 and the slope to be 1 under best cir-
cumstances, this indicates that the normalization procedure
performed very well. For comparison, we also applied the
original BIC-seq to these colorectal data and compared the
results with those from microarray data. Analogous analy-
sis showed that the correlation of log2 tumor/normal ratio
with log2 copy number ratios of the array data is only 0.44
(also see Supplementary Figure S9A). The main reason for
this low correlation is that a substantial proportion of the
tumor/normal genome pairs have different GC-biases, sim-
ilar to what was observed for the sample TCGA-AG-3574
(Figure 1B and Supplementary Figure S5B), and this vio-
lates the assumption of BIC-seq.
Recurrent CNVs and correlation with expression data. To
detect recurrent CNVs in these patients, we applied the
GISTIC algorithm (24) to the segmentation given by BIC-
seq2. Several known arm level alterations have been iden-
tified previously (25), including gains of 7p/q, 8p/q, 13q,
20p/q, deletions of 1p, 4q, 14q, 15q, 17p (including TP53),
21q. We identified 16 focal deletions and 12 focal ampli-
fications with q-values < 0.1 (Supplementary Figure S9B
and C; Supplementary Tables S3 and S4), containing 447
and 165 genes, respectively. For each gene in the focal dele-
tion (amplification) peaks, we identified genes for which
the samples harboring the deletion/amplification have con-
cordant down-regulation/up-regulation of expression com-
pared with the samples without the deletion/amplification.
This resulted in 177 (out of 447) significant genes (P-value<
0.01; Wilcoxon’s signed rank sum test) in the deletion peaks
and 95 (out of 165) genes in the amplification peaks (Sup-
plementary Tables S5 and S6). Fisher’s test shows that these
genes are significantly (P-value 2.5 × 10−5) enriched with
cancer census genes (26). Pathway analysis using DAVID
(27–29) finds that the most significantly altered pathway for
the significant amplification genes is Phosphatidylinositol
(PI) signaling system (P-value = 7.8 × 10−5), a pathway
critical for cancer development (30). The most significantly
altered pathway for deletion genes is the apoptosis pathway
(P-value = 1.5 × 10−6) (Supplementary Table S7).
The genes with concordant transcript up-regulation
and chromosomal amplification include known onco-
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Figure 5. Comparison with arrays and identification of CNVs with expression differences. (A) Comparison with Illumina SNP 6.0 array data. The
tumor/expected-ratio versus seg.mean-value scatter plot for a hundred colorectal genomes is shown. The red line is the fitted median regression line;
the black diagonal line corresponds to y = x. The true positive rate of BIC-seq2 compared to arrays is 90.8% if we treat copy gains (copy losses) with
corresponding seg.mean values greater (less) than 0.2 (−0.2) as true positives. (B) Differences in expression levels in samples with or without the PIK4K2B
amplification and RERE and NPM2 deletions.
genes MYC, IGF2, ERBB2 and HNF4A (31) (Supplemen-
tary Figure S10A). We also identified novel genes that
may be important in colorectal cancers. In particular,
PIP4K2B (phosphatidylinositol-5-phosphate 4-kinase, type
II, beta), whose average expression in the amplified and
non-amplified cases are shown in Figure 5B, is a member of
the phosphatidylinositol-5-phosphate 4-kinase family and
has been shown to be frequently amplified in breast can-
cer. Overexpression of PIP4K2B can confer proliferation
advantage to tumor cells and it may therefore serve as a
drug target for preventing and treating cancers with muta-
tions in TP53 (32,33). Genes whose transcripts show down-
regulation coupled with chromosomal deletions include
cancer-related genes such as ARID1A, SDHB, MAP2K4,
FLCN (Supplementary Figure S10B). ARID1A encodes a
protein involved in chromatin remodeling. It was previously
shown to be frequently mutated and proposed as a tumor
suppressor in a number of cancers (25,34–36). Here, we
found that it is also frequently deleted in colorectal cancers.
In addition, we also identified two additional genes, chro-
matin remodelers RERE and NPM2, as frequently deleted
(Figure 5B). Over-expression of RERE was shown to trig-
ger apoptosis (37) and frequent methylation of NPM2 was
observed in melanoma (38) and leukemia (39).
Germline CNVs with cancer susceptibility
Most importantly, we applied BIC-seq2 to 969 low cover-
age (4X–6X) genomes of peripheral blood samples from the
TCGA cancer patients (these samples are mostly distinct
from the smaller number of high-coverage (30–60X) TCGA
WGS samples). These samples were sequenced mainly to
identify somatic structural variants and the fusions iden-
tified in these samples have been highlighted in several
TCGA papers. Here, we applied our algorithm to iden-
tify germline CNVs that may confer cancer susceptibil-
ity. These genomes span 11 types of cancers including
bladder urothelial carcinoma (BLCA), brain lower grade
glioma (LGG), breast invasive carcinoma (BRCA), colon
and rectum adenocarcinoma (COAD-READ), head and
neck squamous cell carcinoma (HNSC), lung adenocar-
cinoma (LUAD), prostate adenocarcinoma (PRAD), skin
cutaneous melanoma (SKCM), stomach adenocarcinoma
(STAD), thyroid carcinoma (THCA) and uterine corpus en-
dometrial carcinoma (UCEC) (Supplementary Table S8).
One major difficulty in identifying cancer-related CNVs
in these data is to remove population polymorphic sites us-
ing a proper control data set. In this work, we used two
control data sets. The first is the 71090 CNVs we iden-
tified in the above 100 HapMap genomes from the 1000
Genome Project. The second is the CNVs from the database
of genomic variants (DGV). For the DGV CNVs, we only
considered the CNVs that were called in studies with se-
quencing data since CNVs called by array-based technolo-
gies tend to have a lower resolution and their sizes tend
to be overestimated (40,41). Thus, using only those studies
with sequencing datawouldmake the case and controlmore
comparable. This gave us 6213 DGV control samples. The
1000 Genome Project data are helpful for removing CNVs
that are enriched in the case data sets due to algorithm dif-
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ference. The second data are much larger and thus gives us
more power to detect and filter rare events.
We first merged the CNV segments discovered in more
than two cancer patients to form ‘CNV regions’ (CNVR).
Since the predicted CNVs in different samples can have
slightly different boundaries, this merging process gives us
a single region on which we can perform statistical test.
We focused on CNVRs overlapping with protein-coding se-
quences. Since the population structures in the case data set
and the two control data sets can be different and the ma-
jority of cancers are not related to heritable factors (42),
we filtered out CNVRs with a frequency >20%. Since the
first control data set is small and a statistical test based on
this control data would remove rare but true cancer predis-
posing CNVs due to insufficient power, we instead filter the
remaining CNVRs with a frequency cutoff: a CNVR is fil-
tered out if more than 5 samples in the first control data set
have CNVs overlapping with the CNVR. Lastly, Fisher’s
test was used to compare the case CNVs with the DGV
CNVs. Details of the analysis procedure are presented in
the Supplementary Text. Table 1 shows the CNVRs cover-
ing protein-coding regions with a P-value less than 1.0 ×
10−7 as well as significant CNVRs (P-value< 0.05) overlap-
ping with known cancer genes (See Supplementary Table S9
for all of the significant CNVRs).
We identified known as well as novel cancer-predisposing
CNVRs. Among the known CNVRs, the most significant
is the 7p14.1 deletion CNVR overlapping with the gene
TARP (Supplementary Figure S11A). This TARP CNVR
was found to be the most significant germline CNVR in
neuroblastoma (1), and herewe found that it is also enriched
in other tumor types (P-values < 0.01) including COAD-
READ (39/94), HNSC (16/105), LGG (12/48), PRAD
(24/79), SKCM (34/118), STAD (24/114) and UCEC
(25/103). The 7q34 deletion CNVR (Supplementary Fig-
ure S11B) harboring the gene PIP was previously identified
as a potential cancer-predisposing variation by screening of
high-risk cancer patients (43). It was also shown that the ex-
pression of PIP is significantly associated with good prog-
nosis factors of breast cancer such as lower tumor grade
and lower pN stage (44). The 6q37 amplification CNVR
(Supplementary Figure S11C) is also known and is signif-
icantly enriched in Li–Fraumeni symdrome (45). The gene
MLLT4 in this CNVR is well known to be the fusion part-
ner of KMT2A (ALL-1) in acute myeloid leukemias (46).
Novel CNVRs include the most significant CNVR lo-
cated at 7q36.1 overlapping with KMT2C (MLL3) (Sup-
plementary Figure S12A). KMT2C is a well-known cancer-
related gene and it is frequently mutated in many can-
cers such as gastric cancer (47), hepatocellular carci-
noma (48) and cholangiocarcinoma (49). Recent studies
showed that germline mutations in KMT2C might be as-
sociated with ovarian cancer, colorectal cancer and acute
myeloid leukemia (50,51). Here, we find that the CNVR in
KMT2C is enriched (P-values < 0.01) in BLCA (5/106),
BRCA (6/20), HNSC (5/105), LGG(11/48), PRAD (7/79),
SKCM (9/118), STAD (18/114) and UCEC (4/103). The
novel 5p13.3 CNVR (Figure 6A) overlaps with the gene
GOLPH3. High frequency of GOLPH3 amplification was
observed in several solid tumor types such as lung, ovar-
ian, breast, pancreatic, prostate and skin cancers (52). Ex-
tensive studies have validated thatGOLPH3 is an oncogene
(52,53), and over-expression of GOLPH3 is correlated with
poor prognosis inmultiple tumor types (54,55). This CNVR
also overlaps with the gene PDZD2, which was shown to
be highly expressed in prostate cancers and to be associ-
ated with initiation or early promotion of prostate can-
cer (56). Although we found three individuals in the 1000
Genome Project having duplications covering this CNVR,
the duplication of one individual is in fact much larger than
this CNVR (Figure 6A). This CNVR was previously iden-
tified as a risk factor for recurrent miscarriage (57). The oc-
currence frequency of the 5p13.3 CNVR in the Estonian
Biobank control set used in this work (57) is∼1% (9/1000),
while the occurrence frequency in our tumor data is ∼4%
(41/969). Fisher’s test based on this control data gives a P-
value of 2.0 × 10−6. Furthermore, we found that 30 out of
41 cancer patients have at least 2 discordant reads support-
ing an intra-chromosomal translocation with two break-
points involvingGOLPH3 andPDZD2, indicating that this
CNVR may be related with the translocation. GOLPH3
was shown to play an important role in the mTOR signal-
ing pathway (52) and mTOR was known to be an essential
component of mammalian reproductive function (58,59).
Thus, alteration of themTORpathwaymight provide an ex-
planation for conferring both cancer and recurrent miscar-
riage with this GOLPH3 amplification. The 12p12.3 ampli-
fication CNVR overlaps with the gene PLEKHA5; expres-
sion ofPLEKHA5 inmelanomawas shown to be associated
with early development of brain metastasis (60).
In addition, we also identified less significant but novel
CNVRs that overlap with known cancer genes. For exam-
ple, the 8q12.1 CNVR (amplification; P-value: 3.3 × 10−4)
covers the gene PLAG1 (Figure 6B), which is frequently al-
tered in pleomorphic adenomas of the salivary glands as
well as other types of tumors (61). Another is the ampli-
fication CNVR overlapping ERBB2 (HER2). Although 4
patients have CNVs overlapping with this CNVR, only 3
of them cover ERBB2 (Figure 6C). Interestingly, all three
patients are stomach cancer patients. If we only consider
stomach cancer patients, the P-value of this CNVR is 3.0
× 10−4. ERBB2 is well-known to be frequently amplified in
breast cancer and has also been shown to be frequently am-
plified in other types of cancer such as gastric and gastroe-
sophageal cancers (62). While somatic amplification and
overexpression of ERBB2 has served as druggable targets
with monoclonal antibody (Herceptin), the germline copy
number changes have not been well recognized. It may be
associated with germline susceptibility of the disease as
well as the druggability with the ERBB2-targeting agents.
Germline mutations of ERBB2 that may confer cancer risk
were also identified previously, such as in familial lung ade-
nocarcinomas (63).
DISCUSSION
GC bias has been noted previously in many applications
of high-throughput sequencing. Here, we first show that
this problem is pervasive in WGS data, GC-dependence
can take various linear or nonlinear forms and the bias is
experiment-dependent. This makes it difficult to identify
CNVs in a single sample (e.g. germline analysis) or to sim-
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Table 1. Highly significant CNVRs. First eight rows: all genes that overlap with the highly significant CNVRs (P-value < 1E-7); Last three rows: known
cancer-related genes overlapping with significant CNVRs (P-value < 0.05)
Cytoband Start End PC/1KG/DGV* CNV Type Gene P-value
7q36.1 15195749
151990501
68/3/16
7.0%/3.0%/0.3%
Amp KMT2C 6.55E-45
5p13.3 32105400
32168040
41/3/0
4.2%/3.0%/0.0%
Amp PDZD2,GOLPH3 1.02E-36
7p14.1 38283144
38416157
192/1/397
19.8%/1.0%/6.4%
Del TARP 3.08E-36
2q36.3 228240991
228258967
23/0/11
2.4%/0.0%/0.2%
Amp TM4SF20 5.05E-13
3q12.2 100334650
100446463
16/0/2
1.6%/0.0%/0.03%
Amp GPR128,TFG 1.27E-12
7q34 142824400
142894023
20/0/11
2.1%/0.0%/0.2%
Del PIP,TAS2R39 6.48E-11
12p12.3 19467296
19580473
11/0/0
1.1%/0.0%/0.0%
Amp PLEKHA5 2.57E-10
6q27 168332692
168598263
15/1/9
1.5%/1.0%/0.1%
Amp KIF25,MLLT4,HGC6.3,FRMD1 3.21E-08
12q24.13 112180349
112316664
5/0/0
0.5%/0.0%/0.0%
Amp ALDH2 4.43E-05
8q12.1 57050810
57098666
4/0/0
0.4%/0.0%/0.0%
Amp PLAG1 0.00033
17q12 37671717
37918575
4/0/5
0.4%/0.0%/0.08%
Amp ERBB2,CDK12 0.023654
*PC: Pan-Cancer Patients; 1KG: 1000 Genome Project; DGV: Database of Genomic Variants; Numbers shown on the top and on the bottom are the
numbers and the percentages of individuals in each category that have CNVs overlapping with this CNVR.
ply use a matched control to remove germline variants in
somatic variant analysis. To overcome this problem, we de-
veloped a statistical method that can be used to normalize
high-throughputWGSdata at a nucleotide level. Our analy-
sis demonstrates that this normalization procedure can suc-
cessfully capture and remove GC and related biases. Com-
bining this step with a robust segmentation method, our
BIC-seq2 algorithm is capable of detecting CNVs at high
resolution. Although we have shown that BIC-seq2 has bet-
ter performance than other methods, it can be further im-
proved by incorporating the information from the discor-
dant reads (defined above) and split reads (reads that span
a breakpoint).
In the normalization step, BIC-seq2 treats mappability
differently from other methods (11,16). Available methods
often bin the data to equal-sized bins first and treat map-
pability (e.g. as the percentage of uniquely mappable po-
sitions in a bin) essentially as a covariate in a regression
model to remove the mappability bias. BIC-seq2 does not
first bin the data, and mappability is not treated as a covari-
ate of the regression model for the normalization. Instead,
BIC-seq2 performs its normalization at each single uniquely
mappable position, i.e. the expected number of reads is cal-
culated at each mappable position. After normalization, we
typically bin the nucleotide-level normalized data to larger
variable-sized bins (e.g. 10 bp or 100 bp) in the segmentation
step for computational efficiency. We note that nucleotide-
level normalization is advantageous because it allows de-
tection of CNVs with high-resolution. In particular, PEM-
methods often generate small CNV calls, and a nucleotide-
level read-depth normalization method can be used effec-
tively to remove false positives from PEM-methods.
Application of our method to 969 blood genomes of
cancer patients allowed us to confirm known and cancer-
predisposing CNVRs and identify new ones. The novel CN-
VRs cover known cancer related genes such as GOLPH3,
PLAG1 and ERBB2. The CNVRs containing PLAG1 and
ERBB2 are very likely to be true cancer risk amplifications,
even though they are less significant. Especially, the ERBB2
CNVR covers entire ERBB2 gene and the 3 patients are all
stomach cancer patients. A larger data size is needed to con-
firm them being true cancer susceptibility variation. The
main difficulty in identifying cancer predisposing CNVR
using TCGA data is the lack of proper control data. Here,
we used two different control data to filter the common
CNVs. Although the first control data are small in size, it
helped to effectively filter the CNVs that are enriched in the
case but not in the DGV control data due to algorithmic
difference. The threshold 5 used in the first control data can
be restrictive. True but low penetration cancer predisposing
CNVs can be filtered by this threshold. In fact, the germline
deletion of APOBEC3A and APOBEC3B is known to be
associated with modestly increased cancer risk (64), but it
was filtered because 6 individuals in the 1000 Genome con-
trol data have this deletion (Supplementary Figure S12B).
The method used in this work has allowed us discover
both known and novel cancer predisposing CNVRs, but the
highly significant CNVRs might still contain copy number
polymorphism. For example, the CNVR overlapping with
the gene TFGmight be a polymorphism in normal popula-
tion (Figure 6D). The gene TFG is listed as a cancer gene
in the COSMIC (Catalogue of Somatic Mutations in Can-
cer) database (65). There are several documented oncopro-
teins encoded by fusion genes involving this gene, such as
the TFG-NTRK1 gene fusion (66), the TFG-ALK gene fu-
sion (67) and the TFG- NR4A3 gene fusion (68). We found
that 14 out of 16 patients have at least 2 paired-end reads
supporting a gene fusion TFG-GPR128 and so this copy
number change is related to the gene fusion. This gene fu-
sion was identified in typical myeloproliferative neoplasms
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Figure 6. Examples of novel potential cancer-predisposing germline CNVs. (A) GOLPH3, PDZD2 amplification, (B) PLAG1 amplification, (C) ERBB2
amplification and (D) TFG amplification.
but was also found in healthy individuals (69). This CNVR
thus might be a rare polymorphism that we could not prop-
erly filter. On the other hand, among the 16 patients with the
amplification at TFG, 5 of them (2 BLCA patients, 1 LGG
patient and 2 STAD patients) had data on family history
in their clinical annotations. The 2 BLCA patients and the
LGG patient had a family history of cancer; the 2 STAD
patients did not have family history of stomach cancer, but
data were not available on whether there was a history of
any other cancers. These data suggest the possibility that
the TFG CNVR might have a role in cancer development.
Further investigation will be required to elucidate the role
of this CNVR in cancer. Lastly, we emphasize that in addi-
tion to the discussed potential germline CNVs, the CNVs
of cancer patients profiled in this work provide a valuable
resource for future analyses.
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